EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO’s favorable result depended on excluding nine DURAVYU patients.

NEW YORK, Oct. 20, 2026 /PRNewswire/ — Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) have lost roughly 80% of their value after the Company’s Phase 3 LUCIA trial of DURAVYU missed its primary endpoint of non-inferiority to on-label aflibercept in wet age-related macular degeneration. If you bought EYPT and lost money, an investigation is underway and you may have legal rights. Shareholders who lost money are encouraged to submit your EYPT loss details now.

You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

On August 6, 2025, CEO Jay S. Duker told investors that the LUGANO and LUCIA trials were “designed in close alignment with the FDA, including written agreement from the agency to support a clear approval pathway and a compelling label.” In LUCIA, DURAVYU produced approximately +2.5 letters of mean best-corrected visual acuity change. The on-label aflibercept control arm produced approximately +6.1 letters, a shortfall of roughly 3.7 letters on the primary measure.

On August 17, 2026, CEO Jay S. Duker told investors “we also have a lot of confidence in LUCIA. The strength of the ad hoc analysis and the secondary endpoints gives us confidence in hitting the primary endpoint and the secondary endpoints in the upcoming LUCIA trial. We expect to show that data in the fourth quarter of this year.”

On the morning of October 19, 2026, EyePoint disclosed the LUCIA trial did not meet the primary endpoint of mean change in best corrected visual acuity despite visual improvements. Within hours of the announcement, EYPT shares had swiftly fallen fell approximately 80% on the endpoint result.

EYPT investors who suffered losses can request a free review of your losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the EYPT Investigation

Q: Who is eligible to participate in the EYPT investigation?A: Investors who purchased EYPT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: How much did EYPT stock drop?A: Shares fell roughly 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU missed its primary endpoint of non-inferiority to on-label aflibercept. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether EyePoint Pharmaceuticals made materially false or misleading statements regarding the regulatory pathway for DURAVYU, including descriptions of its Phase 3 trial design and its alignment with the FDA. When the Company disclosed that the LUCIA trial missed its primary endpoint, the stock price declined sharply.

Q: What do EYPT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my EYPT shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eypt-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-eyepoint-pharmaceuticals-302913832.html

SOURCE SueWallSt.com